Release Details

Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

August 14, 2023

ReSPECT clinical trial data continues to demonstrate promise for treatment of leptomeningeal metastases and recurrent glioblastoma

Received FDA approval to move into Phase 1/Part B of the ReSPECT-LM clinical trial

Management to host conference call today at 5:00 p.m. ET

AUSTIN, Texas, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the second quarter ended June 30, 2023, and provided an overview of recent business highlights.

“The past 12 months have been transformative for the company,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. “We now have two lead indications, recurrent glioblastoma and leptomeningeal metastases, for our rhenium (186Re) obisbemeda investigational drug and we plan to fully leverage available external third-party funding to move both clinical development programs through Phase 2 and evaluate accelerated approval opportunities.”


Leptomeningeal Metastases

  • Completed Phase 1/Part A of the ReSPECT-LM clinical trial.
  • Presented preliminary safety and efficacy results from Phase 1/Part A of the ReSPECT-LM clinical trial at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference.
  • Received U.S. Food and Drug Administration (FDA) approval to move to Phase 1/Part B of the ReSPECT-LM clinical trial.
  • In the second quarter of 2023, achieved all Year 1 goals and objectives set forth in the Company’s 3-Year, $17.6M Cancer Prevention & Research Institute of Texas (CPRIT) grant.

Recurrent Glioblastoma

  • Presented clinical updates on the ReSPECT-GBM Phase 1 dose escalation and Phase 2b trials for recurrent glioblastoma (GBM) at the SNO/ ASCO CNS Cancer Conference.
  • Announced topline results from our propensity matched, recurrent GBM external control analysis for comparative evaluation of outcomes in our prospective recurrent glioblastoma trials at American Society of Clinical Oncology (ASCO) 2023.

Supply Chain



  • The Company’s cash balance was $10.9 million at June 30, 2023, compared to $18.1 million at December 31, 2022. A second grant payment from CPRIT, in the amount of $1.9 million, has been approved and is expected to be received prior to the end of August 2023.
  • The Company recognized $1.9 million of grant revenue in the second quarter of 2023, which represents the CPRIT’s share of costs incurred in the development of rhenium (186Re) obisbemeda for the treatment of patients with LM.
  • Total operating expenses for the second quarter of 2023 were $3.3 million, compared to total operating expenses of $5.1 million for the same period the prior year. The decrease is due primarily to a decrease in research and development expenses from completion of the initial cGMP development work on rhenium (186Re) obisbemeda.
  • In addition to current cash on hand, the Company benefits from grant awards of $3 million from the National Institutes of Health and $17.6 million from CPRIT. The Company also has discretionary, or stockholder approved access to capital, subject to market conditions and securities laws compliance from its ATM and equity line of credit of at least $49 million. In aggregate, these capital sources could provide sufficient capital to fund currently planned and anticipated activities through 2025, if fully utilized.
  • Net loss for the second quarter of 2023 was $(1.5) million, or $(0.59) per share, compared to a net loss of $(5.3) million, or $(3.56) per share, for the same period the prior year.


During the remainder of 2023, the Company plans to accomplish the following key business objectives:

  • Initiate Phase 1/Part B of the ReSPECT-LM trial.
  • Obtain FDA approval and initiate the Phase 1 ReSPECT-PBC trial for pediatric patients with ependymoma and high-grade glioma at Lurie Children’s Hospital in Chicago.
  • Determine FDA regulatory designation for the 188RNL-BAM development.
  • Add key second source supply chain vendors to support late-stage clinical trials.
  • Publish ReSPECT-GBM Phase 1 data in peer-reviewed publication.
  • Present safety and efficacy data from ReSPECT-GBM trials at the annual SNO conference in Vancouver on November 16-19, 2023.
  • Various data presentations planned for the following 2023 medical meetings: EANM on September 9-13 and CPRIT’s Innovations in Cancer Prevention and Research Conference VI on October 2-3.


The Company will hold a conference call and live audio webcast at 5:00 p.m. Eastern Time today to discuss its financial results and provide a general business update.

A live webcast will be available at

Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company’s website under the 'For Investor' section. The webcast will be available on the Company’s website for 90 days following the live call

About Plus Therapeutics

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a robust supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186Re including the ability of 186Re to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of 186Re; the continued evaluation of 186Re including through evaluations in additional patient cohorts; the intended functions of the Company’s platform and expected benefits from such functions; and matters regarding the Company’s liquidity and access to capital.

The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. The Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, and the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, including because of market conditions and limitations under the securities laws given the Company’s current market capitalization: the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

(in thousands, except share and par value data)
  June 30, 2023  December 31,
Current assets:      
Cash and cash equivalents $10,895  $18,120 
Grant receivable  718    
Other current assets  751   3,697 
Total current assets  12,364   21,817 
Property and equipment, net  1,143   1,324 
Operating lease right-of-use assets  242   248 
Goodwill  372   372 
Intangible assets, net  64   94 
Other assets  12   12 
Total assets $14,197  $23,867 
Liabilities and Stockholders’ Equity      
Current liabilities:      
Accounts payable and accrued expenses $6,580  $10,134 
Operating lease liability  110   110 
Term loan obligation  4,709   1,608 
Total current liabilities  11,399   11,852 
Term loan obligation     3,786 
Noncurrent operating lease liability  136   141 
Deferred grant liability     1,643 
Total liabilities  11,535   17,422 
Stockholders’ equity:      
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively      
Common stock, $0.001 par value; 100,000,000 shares authorized; 2,879,620 and 2,240,092 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively  3   2 
Additional paid-in capital  476,131   473,628 
Accumulated deficit  (473,472)  (467,185)
Total stockholders’ equity  2,662   6,445 
Total liabilities and stockholders’ equity $14,197  $23,867 

(in thousands, except share and per share data)
  For the Three Months Ended June 30,  For the Six Months Ended June 30, 
  2023  2022  2023  2022 
Development revenues:            
Government contracts and other $1,854  $  $2,360  $ 
Operating expenses:            
Research and development  1,420   2,831   4,403   4,615 
General and administrative  1,924   2,289   4,167   4,431 
Total operating expenses  3,344   5,120   8,570   9,046 
Loss from operations  (1,490)  (5,120)  (6,210)  (9,046)
Other income (expense):            
Interest income  120   19   171   26 
Interest expense  (112)  (181)  (246)  (379)
Loss on disposal of property and equipment        (2)   
Change in fair value of liability instruments           1 
Total other income (expense)  8   (162)  (77)  (352)
Net loss $(1,482) $(5,282) $(6,287) $(9,398)
Net loss per share, basic and diluted $(0.59) $(3.56) $(2.60) $(6.43)
Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders  2,509,378   1,483,655   2,415,221   1,461,330 

(In thousands)
  For the Six Months Ended June 30, 
  2023  2022 
Cash flows used in operating activities:      
Net loss $(6,287) $(9,398)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization  318   302 
Amortization of deferred financing costs and debt discount  119   218 
Change in fair value of liability instruments     (1)
Loss on disposal of property and equipment  2    
Stock-based compensation expense  280   347 
Amortization of operating lease right-of-use assets  57   38 
Increases (decreases) in cash caused by changes in operating assets and liabilities:      
Grant receivable  718    
Other current assets  1,510   525 
Accounts payable and accrued expenses  (3,589)  1,527 
Change in operating lease liabilities  (56)  (74)
Deferred revenue  (1,643)   
Net cash used in operating activities  (8,571)  (6,516)
Cash flows used in investing activities:      
Purchases of property and equipment  (108)  (348)
Purchase of intangible assets     (117)
In process research and development acquired     (250)
Net cash used in investing activities  (108)  (715)
Cash flows from financing activities:      
Principal payments of term loan obligation  (804)  (804)
Proceeds from sale of common stock, net  2,258   7,725 
Net cash provided by financing activities  1,454   6,921 
Net decrease in cash and cash equivalents  (7,225)  (310)
Cash and cash equivalents at beginning of period  18,120   18,400 
Cash and cash equivalents at end of period $10,895  $18,090 
Supplemental disclosure of cash flows information:      
Cash paid during period for:      
Interest $135  $168 
Supplemental schedule of non-cash investing and financing activities:      
Unpaid offering cost $35  $50 

Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767 

Media Contact 
Terri Clevenger
ICR Westwicke
(203) 856-4326